NEW YORK, April 6 (GenomeWeb News) - Genaissance Pharmaceuticals said today that it has signed agreements with the University of Rochester and the Mayo Clinic for access to clinical research samples, associated data, and intellectual property around certain disease-associated mutations that it will use in developing genetic tests for cardiac disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.